The investigation goal of the present report is to use the early post-radiation peripheral blood DNA content changes during radiotherapy (RT) of cancer patients for the prognosis of the subsequent leukopenia value. Twenty-three primary patients with II-III stage Hodgkin's disease were treated at the linear accelerator of 15 Mev electrons by usual fractionation to total 40 Gy dose. The blood DNA content was fluorometrically determined by 4', 6-diamidino-2phenylindole before treatment, then 24 hrs after the 1st irradiation dose, in the middle and at the end of RT course. Retrospective analysis of obtained data demonstrated, that the first group of patients, having blood leukocyte levels above 3 x 10(9)/l at the end of RT, revealed an average blood DNA concentration decrease only after the middle of treatment course. The second group of patients, having at the end of RT severe leukopenia, showed an approximately twofold decrease of the DNA concentration after the first irradiation in 62% of cases. The biochemical change was not accompanied by a proportional decrease of the leukocytes amount. The DNA content fall, at the middle and at the end of RT course, was conditioned both by lymphocytes and granulocytes. These changes were not practically interfaced with plasma changes. Thus, a given biochemical criterium may be used as a sensitive index for the prognosis of leukopenia values after the RT beginning. Such a conclusion was confirmed by in vitro test-irradiation of blood specimens of primary patients with Hodgkin's disease. A significant correlation was found between the new index and the level of leukopenia of the patient's blood during post-treatment course.
Download full-text PDF |
Source |
---|
Diabetes Obes Metab
January 2025
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Diseases in the Population, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Background: Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories of steatotic liver disease (SLD) recently proposed by nomenclature consensus group and cancer risk.
Methods: A total of 283 238 participants from the UK Biobank were included.
Br J Haematol
January 2025
Department of Nursing, Tohoku Fukushi University, Sendai, Japan.
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.
View Article and Find Full Text PDFTransplant Cell Ther
January 2025
Institute of Haematology, Royal Prince Alfred Hospital, SLHD, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
CD19 directed chimeric antigen receptor (CAR) T-cell therapy is now standard of care for relapsed/refractory large B-cell non-Hodgkin lymphoma. Despite good overall response rates, many patients still experience disease progression and therefore it is important to predict those at risk of relapse following CAR T-cell therapy. We performed a prospective study using a flow cytometric assay at a single treatment centre to assess early CAR T-cell expansion in vivo 6 - 9 days after CAR-T cell infusion.
View Article and Find Full Text PDFPract Radiat Oncol
January 2025
The Legacy Heritage Oncology Center & Dr Larry Norton Institute, Soroka University Medical Center, Ben Gurion University of the Negev, Faculty of Medicine, Be'er Sheva, Israel.
Purpose: Continuous advancements in cancer management have resulted in increased long-term survival rates amongst cancer survivors and in turn have exposed the full extent of radiotherapy-associated morbidities. Radiation-induced coronary heart disease (RICHD) is one of the leading causes of morbidity and mortality in cancer survivors, particularly in those having undergone mediastinal radiation. While mediastinal radiation has been shown to substantially reduce both recurrence and mortality rates in multiple thoracic malignancies, the risk for the development of RICHD is of significant concern.
View Article and Find Full Text PDFClin Nucl Med
November 2024
From the Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai West, New York, NY.
Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive EBV-associated non-Hodgkin lymphoma, most commonly arising from within the mucosa of the upper aerodigestive tract, typically with nasal presentation. Here, we present an interesting case of a 36-year-old man with ENKTCL with an atypical pattern of disease progression despite 3 cycles of SMILE chemotherapy. Restaging 18F-FDG PET/CT demonstrated widespread uptake within the skeletal musculature in a distribution concerning for a paraneoplastic polymyositis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!